Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA5161||ECOG-ACRIN||Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-P-0011||RTOG||Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S1416||SWOG||Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1802||SWOG||Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-10501||CALGB||A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease <br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA2161||ECOG-ACRIN||A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A151804||Alliance||Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0600||SWOG||Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-HN007||NRG||An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A021502||Alliance||Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*)||Adult CIRB - Late Phase Emphasis||Available to Open|